Navigation Links
IsoPlexis Obtains Exclusive License to Breakthrough Single-Cell Metabolomics Analysis Technologies From Dr. James Heath’s Lab at Caltech
Date:3/27/2017

IsoPlexis Corporation (IsoPlexis), a venture capital-funded life sciences company dedicated to accelerating the fight against cancer, autoimmune disease and more through a single-cell precision engineering platform, today announced it has received an exclusive license to the single-cell metabolomics and proteomics analysis platform developed in the laboratory of Dr. James Heath at the California Institute of Technology, a pioneer in applying chemical physics to biological problems.

Dr. James Heath’s new inventions enable detection of multiple types of metabolite information from single cells, a capability that aligns well with the IsoCode technology, previously referred to as the SCBC (single-cell barcode chip) solution and the foundation of IsoPlexis’ technologies.

The metabolomics analysis platform provides the ability to track novel metabolite biomarkers involved in the progression of various cancers. The technology’s ability to monitor glioblastoma progression has been detailed in peer-reviewed journals, such as the Journal of the American Chemical Society (JACS).

Sean Mackay, IsoPlexis’ Chief Executive Officer, said, “Dr. Heath’s metabolomics innovations provide yet another critical source of novel information to help clinicians understand the progression of cancer in subsets of cells. Working with a pioneering technical institution like Caltech and developing these highly precise detection solutions with Dr. Heath is just one example of how we’re working to accelerate the fight against cancer.”

Dr. James Heath, Elizabeth W. Gilloon Professor of Chemistry at Caltech, was named one of the seven most powerful innovators of the world by Forbes magazine in 2009. Previously, he founded the California NanoSystems Institute at UCLA and was awarded the prestigious Feynman Prize in Nanotechnology as the co-architect of the first quantum-based, molecular computer switch.

More recently, Dr. Heath has applied his expertise in chemical physics and nanotechnologies to advancing the field of translational medicine, with a specific focus on detecting early stages of resistance in cancers and harnessing the power of the immune system to fight cancer. His breakthrough single-cell analysis platform advances the rapidly growing field of metabolomics, which is seen as critical to developing personalized oncology treatments and monitoring cancer progression. Dr. Heath also sits on the IsoPlexis Board of Directors and Scientific Advisory Board.

Dr. James Heath said, “Several metabolic processes are highly elevated during many transitions from health to disease, and some metabolic signals can even play roles in suppressing anti-cancer immune responses. However, metabolites are small molecules and, unlike proteins, aren’t easily connected to the genetic code. The ability to monitor both metabolites and proteins from the same single cells allows us to begin establishing such connections. Adding additional engineering innovation to the IsoCode technology uniquely positions IsoPlexis to help advance precision medicine, and I am excited we are working together to address some of today’s toughest problems.”

ABOUT ISOPLEXIS:
IsoPlexis is a life sciences company committed to advancing groundbreaking research and therapeutic development in immunology, oncology and other emerging disease areas. The IsoPlexis cellular response analysis platform was developed by scientific leaders at Yale and Caltech. By isolating single immune cells and analyzing their functional omic response, the platform can assess safety and efficacy of therapeutics and monitor disease progression, enabling improved therapeutic development and patient outcomes. Through collaborations with leading pharmaceutical companies and academic labs, the IsoPlexis technology is improving the targeting of breakthrough treatments. The venture capital-funded Yale spinout is headquartered in Branford, Connecticut. For additional information on IsoPlexis, visit http://www.isoplexis.com or email info(at)isoplexis(dot)com.

Read the full story at http://www.prweb.com/releases/2017/03/prweb14187610.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. IsoPlexis Awarded NIH SBIR Grant to Develop Cellular Analysis Platform to Diagnose and Monitor Alzheimer’s
2. GraftWorx Obtains a Pioneer of Sensor Technology and a Key Leader in MEMS
3. Sinovac Obtains Clinical Trial Approval for Sabin-IPV Candidate
4. DS Biopharma Obtains a Granted Patent Covering the Use of DS102 to Treat Fatty Liver Disorders
5. Kultevat obtains license of gene switch technology
6. Avexegen Therapeutics Announces Exclusive License Agreement with Children’s Hospital Los Angeles
7. ThermaGenix, Inc. Announces Start-up and Exclusive Licenses from Brandeis University
8. Immunomedics Enters into Exclusive Global Licensing Agreement with Seattle Genetics for Sacituzumab Govitecan (IMMU-132) with Potential Payments of up to Approximately $2 Billion, Plus Royalties
9. Collective Medical Technologies Edie (a.k.a. PreManage ED) Solution is Exclusively Endorsed by the American College of Emergency Physicians
10. AxioMed Announces 15-year Exclusive Worldwide License on Proprietary Viscoelastic Material with the patent holder DSM
11. Pillar Clinical Research Selects Verified Clinical Trials As Exclusive Provider To Reduce Professional Subjects From Duplicate Enrollment In Their Clinical Trials.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ... and pregnancy rates in frozen and fresh in vitro fertilization (IVF) ... maternal age to IVF success. , After comparing the results from the fresh ...
(Date:10/10/2017)... ... October 10, 2017 , ... For the second ... a US2020 STEM Mentoring Award. Representatives of the FirstHand program travelled to Washington, ... from US2020. , US2020’s mission is to change the trajectory of STEM education ...
(Date:10/10/2017)... ... October 10, 2017 , ... USDM Life ... for the life sciences and healthcare industries, announces a presentation by Subbu Viswanathan ... The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present a revolutionary ...
(Date:10/9/2017)... ... October 09, 2017 , ... At its national board meeting in North ... in Harvard University’s Departments of Physics and Astronomy, has been selected for membership in ... winning team for the 2015 Breakthrough Prize in Fundamental physics for the discovery of ...
Breaking Biology Technology:
(Date:4/13/2017)... Calif. , April 13, 2017 UBM,s ... York will feature emerging and evolving technology ... Both Innovation Summits will run alongside the expo portion ... speaker sessions, panels and demonstrations focused on trending topics ... largest advanced design and manufacturing event will take place ...
(Date:4/11/2017)... MELBOURNE, Florida , April 11, 2017 ... "Company"), a security technology company, announces the appointment of independent ... John Bendheim to its Board of Directors, furthering the ... ... behalf of NXT-ID, we look forward to their guidance and ...
(Date:4/4/2017)... 2017   EyeLock LLC , a leader of ... States Patent and Trademark Office (USPTO) has issued U.S. ... of an iris image with a face image acquired ... company,s 45 th issued patent. ... given the multi-modal biometric capabilities that have recently come ...
Breaking Biology News(10 mins):